GAUDIUMIVF NSE filing

Gaudium IVF Q2 FY27 Revenue up 17.9% to ₹37.4 Cr; Expands with Two New Hubs

The RealCase readHigh impact Positive

Gaudium IVF reported Q2 FY27 revenue of ₹37.4 crore, up 17.9% YoY. H1 FY27 revenue reached ₹56.8 crore, up 14.7% YoY. The company opened two new hubs in Delhi and Gurugram and plans further expansion. EBITDA was ₹13.5 crore with a 36% margin. Clinical pregnancy success rate improved to 62%.

Why it matters

The announcement includes significant financial performance updates, strategic expansion initiatives, and reaffirmation of future guidance, all of which are material for investors.

The market read

The company reported strong revenue growth, successful expansion with new hubs, and improved clinical outcomes. Despite some front-loaded costs due to expansion, the overall outlook and financial health remain positive.

Gaudium IVF and Women Health Limited reported its Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. The company held an Earnings Conference Call on November 16, 2026, to discuss these results.

During the second quarter of FY27, Gaudium IVF saw a significant 17.9% year-on-year increase in revenue from operations, reaching ₹37.4 crore. For the first half of FY27, revenue grew by 14.7% year-on-year to ₹56.8 crore. The core IVF business, reported in standalone results, showed robust growth with revenue up 22.3% year-on-year to ₹28.1 crore in Q2 FY27 and 18.5% year-on-year to ₹41.7 crore in H1 FY27.

The company opened two new hubs in South Extension, New Delhi, on July 16, 2026, and in Gurugram on September 24, 2026. These new centers are built on the Gaudium Signature Lab framework, incorporating AI-led embryology tools like SiD and ERICA, aiming to provide consistent, high-quality fertility care. The South Extension hub is nearing break-even within 2.5 months of its launch, and the Gurugram hub is expected to follow a similar trajectory. The company reported an EBITDA of ₹13.5 crore for Q2 FY27 with a margin of 36%, which included one-off rollout expenses for the new hubs. The clinical pregnancy success rate on the first IVF attempt has improved to 62% following the introduction of AI tools.

As of September 30, 2026, Gaudium IVF operated a network of 9 hubs and 38 spokes. The company plans to open five more centers in Lucknow, Kolkata, Guwahati, Surat, and Hyderabad. The Gaudium Women Hospital in Lucknow is planned with an estimated project cost of up to ₹15 crore, with commercialization expected in FY28-29. The company reaffirms its FY27 revenue guidance of ₹130 crore.

Financially, the consolidated debt-to-equity ratio remains low at 0.03 times. As of September 30, 2026, cash and cash equivalents were ₹20.5 crore, with an additional ₹39.5 crore of unutilized IPO proceeds. The company has utilized ₹50.7 crore of its ₹90 crore IPO funds for new centers, debt repayment, and general corporate purposes.

During the Q&A session, management discussed plans for future expansion, revenue growth aspirations of around 25% for FY28 and FY29, and the potential for existing centers to double revenue without additional capex. The average revenue per patient for Q2 FY27 was ₹3.07 lakhs. The company is also focusing on managing receivables, aiming to reduce them to around ₹10 crore, and has introduced a unique private insurance player model for IVF treatments. The company anticipates maintaining historical margins by the end of the year, despite temporary pressures from expansion and marketing investments.

Filing to action

What to do with a filing like this

Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.

View original filing